iih glp-1 Exenatide (a receptor agonist) rapidly lowered intracranial pressure in active IIH, with a sustained signal at 12 weeks and no meaningful weight change. The authors suggest an ICP-lowering GLP-1s may manage idiopathic intracranial

Self-monitoring of blood glucose is particularly important for patients on concomitant insulin or sulfonylureas, as GLP-1 therapy may necessitate dose reductions of these medications to prevent hypoglycemia

PMID 30506340

Improved Metabolic Health In addition to weight loss, GLP-1 medications may help improve several metabolic health markers, including: Blood sugar levels HbA1c Blood pressure Triglycerides These benefits may be especially valuable for patients managing pre-diabetes or metabolic syndrome

How have Medicaid prescriptions and gross spending on GLP-1s changed in recent years

The safety considerations around peptide medications are serious, and unregulated products carry real risks including contamination, incorrect dosing, and lack of sterility

This hormone promotes insulin and suppresses glucagon